Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they are tested through rigorous randomized controlled trials to ensure safety and effectiveness. After validation, the company seeks FDA clearance to market these applications as class II medical devices. Unlike traditional pharmaceuticals, Click Therapeutics' products are prescribed by physicians and reimbursed by payers, allowing for a unique revenue model. The company collaborates with established pharmaceutical firms, such as Boehringer Ingelheim, to enhance the development and commercialization of their digital therapeutics. The goal of Click Therapeutics is to provide effective, evidence-based software solutions that address unmet medical needs and improve patient outcomes.

Sanofi Ventures

K2 HealthVentures

HSBC Innovation Banking

Standard Treasury

Flatiron Investors

Magellan Health Services

Small Business Innovation Research (SBIR)

Hikma Ventures

Accelmed

Ridgetop Health

Health Catalyst Capital

Revelation Partners

H.I.G. BioVentures

Biotechnology

Healthcare

Click Therapeutics

Click Therapeutics launches Software-Enhanced Drug therapies.

Click Therapeutics Launches Software-Enhanced Drug Therapies

NEW YORK-(BUSINESS WIRE)-David Benshoof Klein, founder and chief executive officer of Click Therapeutics, has been honored as a PharmaVoice 100 winner.

Click Therapeutics Founder and CEO David Benshoof Klein Named to 2024 PharmaVoice 100 List

PRINCETON, N.J. & NEW YORK-(BUSINESS WIRE)-Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) announce today the commercial launch of Rejoyn(TM).

Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn(TM), the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

- Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.

Click Therapeutics Acquires Better Therapeutics, Expands into Obesity and Cardiometabolic Disease

What You Should Know:– Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.– Click’s expansion into cardiometabolic disease follows successful DTx development efforts in other areas, including migraine prevention, depression, schizophrenia, and opioid use disorder.Strengthening the DTx PipelineThe acquisition includes several key assets from Better Therapeutics:AspyreRx (BT-001): The first FDA-authorized DTx for type 2 diabetes.The first FDA-authorized DTx for type 2 diabetes. BT-004: A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH).A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH). BT-002: A DTx designed to reduce blood pressure in patients with hypertension.A DTx designed to reduce blood pressure in patients with hypertension. BT-003: A DTx focused on lowering LDL cholesterol in patients with hyperlipidemia.The strategic acquisition significantly expands Click’s DTx portfolio, complementing their existing offerings in psychiatry, CNS, and pain management. It also strengthens their position in the rapidly growing market for obesity and cardiometabolic disease treatments.A Personalized Approach to Weight ManagementClick’s existing DTx solutions focus on psychiatry, CNS, and pain disorders. By integrating Better Therapeutics’ assets, Click gains immediate traction in the rapidly growing cardiometabolic space, complementing their current offerings.Click emphasizes the importance of personalized treatment plans for obesity, a complex chronic disease

Click Therapeutics Acquires Better Therapeutics, Expands Into Obesity And Cardiometabolic Disease

NEW YORK--(BUSINESS WIRE)--Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc. The assets acquired include AspyreRx (BT-001), the first FDA-authorized prescription digital therapeutic for type 2 diabetes, and BT-004, which was recently granted FDA Breakthrough Device Designation for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Other assets are BT-002, for the reduction of blood pressure in patients with hypertension, and BT-003, for the reduction of LDL cholesterol in patients with hyperlipidemia. This acquisition strengthens Click’s portfolio of innovative digital treatments for patients by immediately advancing its pipeline in obesity, diabetes and cardiometabolic diseases, complementing existing assets in psychiatry, CNS and pain disorders. Click’s advancement into obesity and cardiometabolic disease is a culmination of progress over the past few years including the initiation of CT-181, a prescription digital therapeutic candidate for obesity

Click Therapeutics Accelerates Expansion Into Obesity And Cardiometabolic Disease With Acquisition Of The Assets Of Better Therapeutics, Inc.

SAN FRANCISO--(BUSINESS WIRE)--Otsuka America, Inc. (OAI) announces Otsuka Precision Health, Inc. (OPH), a company that will serve as a catalyst for delivering the right interventions at the right time along patients’ and caregivers’ unique health journeys, ranging from connected health solutions to digital therapeutics, all powered by advanced analytics tools like artificial intelligence. OPH will focus on the patient experience as a core piece of improving how better outcomes might be achieved across nephrology, mental health, and beyond. The recent U.S. Food and Drug Administration (FDA) clearance of Rejoyn™, the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder (MDD) symptoms, is a proof-point for the possibilities of what OPH can bring to the market to enable a better patient experience

Otsuka America, Inc'S. Data And Technology Company Will Support Rejoyn(Tm) Commercialization & Personalized Patient Engagement

PRINCETON, N.J. NEW YORK--(BUSINESS WIRE)--Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn™ (developed as CT-152), the first prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. Rejoyn is intended to reduce MDD symptoms

Otsuka And Click Therapeutics Announce The U.S. Food And Drug Administration (Fda) Clearance Of Rejoyn™, The First Prescription Digital Therapeutic Authorized For The Adjunctive Treatment Of Major Depressive Disorder (Mdd) Symptoms

Click Therapeutics **** David B. Klein, Founder & CEO.

Revenue Cycle and Payer News - January 3, 2024

Click Therapeutics today announced that it has secured $20 million debt financing from HSBC.

Click Therapeutics Secures $20 Million Debt Financing from HSBC

Develops software as prescription medical treatments

Click Therapeutics

Develops software as prescription medical treatments

Click Therapeutics

Develops software as prescription medical treatments

About

Simplify's Take

What believers are saying

What critics are saying

What makes Click Therapeutics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Click Therapeutics is Hiring for 0 Jobs on Simplify!